<PublisherName>Pharmaceutical and Biological Evaluations</PublisherName>
<JournalTitle>Pharmaceutical and Biological Evaluations</JournalTitle>
<ArticleTitle>Influence of hmg co-a inhibitor pitavastatin on pharmacodynamics and pharmacokinetics of pioglitazone in rats and rabbits</ArticleTitle>
<FirstName>Venkata Sunil Kumar</FirstName>
<Affiliation>Vishnu Institute of Pharmaceutical Education & Research, BVRIT, Narsapur, Medak, Telangana. venkatasunilkumar@gmail.com</Affiliation>
<LastName>Reddy Y</LastName>
<Abstract>Objective: The study was conducted in rats and rabbits with selected oral doses of Pioglitazone and Pitavastatin their combination to evaluate the safety of Pioglitazone therapy in the presence of Pitavastatin.Methods: Blood samples were collected from rats/rabbits by retro orbital/marginal ear vein puncture respectively at regular intervals of time. The blood glucose was estimated by GOD/POD method and serum Pioglitazone levels by HPLC method.Results:  Pitavastatin showed to reduced blood glucose levels alone and with combination of Pioglitazone in both normal rats and diabetic rats. The serum Pioglitazone levels were increased significantly and pharmacokinetic parameters like AUC, Cmax, Ka, Cl and increase in the T1/2 of Pioglitazone were not altered significantly in presence of Pitavastatin.Conclusion: The combination might be safe with respect to its hypoglycemic effect; so the doses of Pioglitazone and Pitavastatin are advised to safe when co administered in a clinical situation.</Abstract>
<Param>Pioglitazone, Pitavastatin, Blood Glucose</Param>




  • There are currently no refbacks.

Copyright (c) 2016 Pharmaceutical and Biological Evaluations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Creative Commons License


© Copyright 2018 - Pharmaceutical and Biological Evaluations